Key Highlights
● Spruce Biosciences reported $96.3 million in cash as of June 30, 2026, and plans to submit a Biologics License Application for TA-ERT in MPS IIIB (Sanfilippo Syndrome Type B) in the fourth quarter of 2026.
● Palisade Bio reported $125.2 million in cash as of June 30, 2026, funding its Phase 2 ASCENTRA-UC and ASCENTRA-CD trials of oral candidate PALI-2108 in ulcerative colitis and Crohn's disease through both primary readouts.
● Damora Therapeutics, formerly Galecto, holds roughly $535 million in cash as of February 28, 2026, following a $285 million private Investment and a $316 million public offering, funding its anti-mutCALR antibody programs into Phase 3.
● Obsidian Therapeutics went public through an August 3, 2026 Reverse merger with Galera Therapeutics paired with a $350 million private placement, advancing its OBX-115 tumor-infiltrating lymphocyte therapy toward 2027 data.
Five small clinical-stage names on the Nasdaq trace a single 2026 storyline: rare-disease enzyme therapy, oral gut drugs, cancer combinations, blood-cancer antibodies and engineered cell therapy, freshly financed, catalyst-heavy, and far from proven.
The Small-Cap Biotech Story Behind Five Tickers
Two of the five tickers in this basket do not belong to the companies a casual reader might assume. PALI is Palisade Bio, not Palatin Technologies (which trades as PTN). DMRA is Damora Therapeutics, the former Galecto, not Dermata Therapeutics (which trades as DRMA). The other three, FTH and OBX especially, are recently renamed or freshly public shells. Getting the names right is the whole point. What links the correct five is not a single disease but a moment: clinical-stage developers with binary data ahead, most of them recapitalized in 2026, all listed on the Nasdaq and all still years from a product. This is where biotech risk lives.
A Biotech Tape That Rewards Cash and Catalysts
The 2026 backdrop matters. Market commentary through the year described a broad recovery in biotech equities after a punishing multi-year drawdown, with sector funds such as the SPDR S&P Biotech fund (XBI) rallying and analysts pointing to a rebound in dealmaking and IPO activity. Several outlets tied the improving tone to expectations of lower interest rates, which historically matter more to long-duration, cash-burning developers than to almost any other Equity group.
That is analysis, not fact, and it cuts two ways. A friendlier financing window is exactly what let companies like the ones below raise nine-figure sums or reverse-merge onto the Nasdaq. It does nothing to change the underlying biology. Micro-cap and small-cap biotech remains a Business of binary readouts, FDA decisions that can arrive as approvals or refuse-to-file letters, and balance sheets that must outlast the next trial. The five names here sit at different points on that spectrum, and encouragingly, none of the filings reviewed carried a going-concern warning.
Spruce Biosciences (NASDAQ:SPRB): Betting Everything on a Rare Pediatric Disease
Spruce Biosciences has narrowed to a single, high-stakes program: TA-ERT, or tralesinidase alfa, an enzyme replacement therapy for MPS IIIB (Sanfilippo Syndrome Type B), a fatal pediatric neurodegenerative disorder. The asset carries FDA Breakthrough Therapy and Rare Pediatric Disease designations, and management has said it anticipates submitting a Biologics License Application in the fourth quarter of 2026, seeking potential Accelerated Approval based on a cerebrospinal-fluid biomarker.
Alongside the filing, Spruce expects to initiate its TrAnsform confirmatory study in Q4 2026, enrolling roughly 14 children aged one to five, and to launch an Expanded Access Program for about 10 patients. The company reported $96.3 million in cash at June 30, 2026, up from $48.9 million at year-end 2025, with runway stated into the second half of 2027. That jump reflects an April 2026 public offering of $60 million gross (1,150,000 shares at $50.00, plus pre-funded warrants) and a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society.
The setup is classic single-asset biotech: an accelerated-approval path is a genuine catalyst, but a CSF-biomarker filing invites regulatory scrutiny, and a confirmatory trial still has to read out. This is a one-shot story.
Palisade Bio (NASDAQ:PALI): Pushing an Oral Gut Drug Into Phase 2
Palisade Bio is a focused inflammatory-bowel-disease play. Its lead candidate, PALI-2108, is described as a once-daily oral, locally activated PDE4 inhibitor prodrug engineered to switch on in the lower intestine, aiming to concentrate activity where inflammation lives while limiting systemic exposure. In an early Phase 1 signal the company has highlighted, five of five ulcerative colitis patients achieved a clinical response and two reached remission, an encouraging but very small dataset that should not be over-read.
The near-term catalysts are operational rather than data-driven. The FDA cleared the IND for the global Phase 2 ASCENTRA-UC study in ulcerative colitis, with first-patient enrollment expected in the second half of 2026 and primary efficacy results not anticipated until the second half of 2027. A companion Crohn's disease study, ASCENTRA-CD, has an IND submission targeted for H2 2026 and a primary readout expected as late as early 2028.
Crucially, Palisade Bio reported $125.2 million in cash at June 30, 2026, which management says funds operations through both Phase 2 primary readouts. For a clinical-stage micro-cap, financing the trial about to start is half the battle; efficacy remains the other, unproven half.
Faeth Therapeutics (NASDAQ:FTH): Reinventing Sensei Around a Cancer Combination
Faeth Therapeutics is the new identity of Sensei Biotherapeutics, which traded as SNSE before adopting the Faeth name and beginning trading under its current ticker on June 16, 2026. The transformation came via a February 2026 Acquisition of privately held Faeth and a roughly $200 million concurrent private placement, a full strategic reset rather than a cosmetic rebrand.
The lead asset, PIKTOR, is an all-oral combination of serabelisib (a PI3K-alpha inhibitor) and sapanisertib (an mTORC1/mTORC2 inhibitor) that targets the PI3K/AKT/mTOR pathway, one of the most frequently altered signaling routes in cancer. Development is focused on advanced endometrial cancer and HR+/HER2-negative advanced breast cancer. The most immediate catalyst is topline data from the Phase 2 endometrial-cancer trial, anticipated in the second half of 2026; a Phase 1b/2 breast-cancer study dosed its first patient in April 2026, with interim data expected in 2027.
The reconstituted board notably added former FDA Commissioner Stephen M. Hahn, M.D. Combining two pathway inhibitors raises efficacy hopes and tolerability questions in equal measure, and a near-term readout makes Faeth one of the more binary names in this group.
Damora Therapeutics (NASDAQ:DMRA): The Best-Funded Name Here
Damora Therapeutics is the former Galecto, Inc. (previously GLTO), which changed its name and ticker effective March 10, 2026 after acquiring privately held Damora in November 2025. The company is building around mutant calreticulin (mutCALR), a driver of certain blood cancers. Its lead antibody, DMR-001, targets essential thrombocythemia and myelofibrosis and is described by the company as having best-in-class potential against both Type 1 and Type 2 mutCALR, with follow-on candidates DMR-002 and DMR-003 behind it.
The timelines are early: an IND/CTA for DMR-001 was targeted for mid-2026, DMR-002 for the second half of 2026, and DMR-003 for 2027, with the first clinical proof-of-concept datasets for DMR-001 expected to begin around mid-2027.
What sets Damora apart is the balance sheet. The company reported roughly $535 million in cash as of February 28, 2026, following a $285 million private investment in November 2025 and a $316 million public offering in February 2026, with runway said to extend into Phase 3 development of DMR-001. That is an unusually deep war chest for a company still submitting first INDs. It removes near-term financing risk but concentrates the story entirely on whether the anti-mutCALR thesis translates into clinical data.
Obsidian Therapeutics (NASDAQ:OBX): Arriving on Nasdaq Through Galera
Obsidian Therapeutics is the newest listing of the five, having gone public through a reverse merger with Galera Therapeutics (the former GRTX) that closed on August 3, 2026, paired with a $350 million concurrent private Placement backed by institutional investors including Balyasny Asset Management, Caligan Partners, Eventide Asset Management and Nantahala Capital.
The scientific centerpiece is OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy that extracts a patient's own tumor-fighting immune cells, engineers them, and reinfuses them. Obsidian is pursuing both melanoma and non-small cell lung cancer. On the catalyst calendar, the company points to Phase 1 NSCLC data in the first half of 2027 and topline results from a melanoma registration-enabling trial by the end of 2027.
Post-merger ownership tells the structural story: legacy Obsidian equityholders hold roughly 53.2%, PIPE investors about 45%, and Galera's former shareholders only around 1.8%. Cell therapy is capital-intensive and operationally complex, and this company's meaningful readouts sit further out than most of its peers here, making it a 2027 story that happens to trade today.
What Investors Should Watch
The near-term catalyst clock is uneven. Spruce's planned Q4 2026 BLA submission and Faeth's second-half-2026 endometrial topline are the events closest at hand; both are genuinely binary. Palisade's value hinges on trial execution now and efficacy in 2027, while Damora and Obsidian are largely 2027 stories, with the first two firing INDs and the third feeding a cell-therapy pipeline.
Watch financing quality, not just cash headlines. Damora's roughly $350 million PIPE, Faeth's roughly $125.2 million and Spruce's $96.3 million are smaller but each claims runway past a key readout. Also watch dilution mechanics: Spruce's $50-per-share April raise and the reverse-merger share structures at Faeth, Damora and Obsidian mean the share counts and ownership splits deserve as much attention as the science. None of the reviewed filings flagged going-concern doubt, and none disclosed a recent reverse split, but micro-cap Nasdaq compliance can change fast.
Capital Is No Longer the Constraint for This Group
All five are Nasdaq-listed, clinical-stage developers with disclosed 2026 to 2028 catalysts and, per their latest filings, no going-concern warnings. The group is better capitalized than the distressed micro-cap label might suggest, thanks to a friendlier 2026 financing window, but capital buys time, not proof. The names with the nearest readouts, Spruce and Faeth, carry the sharpest near-term risk and reward, while Damora and Obsidian trade the deepest balance sheets for the longest waits. Every thesis here still rests on data that does not yet exist.






Please wait processing your request...